2. Search Result
Search Result
Results for "

PD-L1-IN-3

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155101
    PD-L1-IN-3

    		PD-1/PD-L1 Cancer
    PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC50 value and EC50 value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research .
    PD-L1-IN-3
  • HY-103048A
    PD-1/PD-L1-IN 3 TFA

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .
    PD-1/PD-L1-IN 3 TFA
  • HY-110125
    ML-193

    CID 1261822

    		 GPR55 Neurological Disease
    ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC50 of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats .
    ML-193
  • HY-N0460
    1-Caffeoylquinic acid
    1 Publications Verification

    		 NF-κB Cancer
    1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with Ki of 0.002 μM and binding energy of 1.50 Kcal/mol . 1-Caffeoylquinic acid has anti-oxidative stress ability . 1-Caffeoylquinic acid inhibits PD-1/PD-L1 interact .
    1-Caffeoylquinic acid
  • HY-75502
    Rotigotine
    1 Publications Verification

    N-0923; (-)-N 0437

    		 Dopamine Receptor Adrenergic Receptor 5-HT Receptor Neurological Disease Endocrinology
    Rotigotine is a potent dopamine receptor agonist with Ki values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research .
    Rotigotine
  • HY-103048
    PD-1/PD-L1-IN 3

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .
    PD-1/PD-L1-IN 3
  • HY-156151
    CYP51/PD-L1-IN-3

    		Fungal Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-3 (compound L21) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-3 is a dual inhibitor of CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-3 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
    CYP51/PD-L1-IN-3
  • HY-P990698
    Umizortamig

    		PD-1/PD-L1 EGFR Inflammation/Immunology
    Umizortamig is an anti-CD3E/EGFR/TNFRSF9/PD-L1/CD3G monoclonal antibody .
    Umizortamig
  • HY-145240
    eIF4E-IN-1

    		Eukaryotic Initiation Factor (eIF) Infection Cancer
    eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) .
    eIF4E-IN-1
  • HY-N0460R
    1-Caffeoylquinic acid (Standard)

    		NF-κB Cancer
    1-Caffeoylquinic acid (Standard) is the analytical standard of 1-Caffeoylquinic acid. This product is intended for research and analytical applications. 1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with Ki of 0.002 μM and binding energy of 1.50 Kcal/mol . 1-Caffeoylquinic acid has anti-oxidative stress ability . 1-Caffeoylquinic acid inhibits PD-1/PD-L1 interact .
    1-Caffeoylquinic acid (Standard)
  • HY-75502R
    Rotigotine (Standard)

    		Dopamine Receptor Adrenergic Receptor 5-HT Receptor Neurological Disease Endocrinology
    Rotigotine (Standard) is the analytical standard of Rotigotine. This product is intended for research and analytical applications. Rotigotine is a potent dopamine receptor agonist with Ki values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research .
    Rotigotine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: